Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial (vol 7, e214761, 2021)

被引：0
|
作者：
Feng, Jean [1 ]
Friesner, Isabel [1 ]
Hong, Julian C. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1443 / 1443
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial
    Fang, Wenfeng
    Zhao, Yuanyuan
    Huang, Yan
    Zhang, Yaxiong
    Hong, Shaodong
    Huang, Yihua
    Zhao, Hongyun
    Yang, Yunpeng
    Zhao, Shen
    Chen, Gang
    Zhou, Huaqiang
    Ma, Yuxiang
    Zhou, Ningning
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] A real-world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and<sc> EGFR </sc>exon<sc> 20 </sc>insertion mutations
    Suay, Guillermo
    Martin-Martorell, Paloma
    Aparisi, Francisco
    Arnal, Maria
    Guirado, Maria
    Azkarate, Aitor
    Garde-Noguera, Javier
    Cumplido-Buron, Jose David
    Insa, Amelia
    Gonzalez-Munoz, Jose Francisco
    Palanca, Sarai
    Diaz, Maria
    Sanchez-Hernandez, Alfredo
    Juan-Vidal, Oscar
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [23] Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial
    Mok, Tony
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Rosell, Rafael
    Jaime, Jesus Corral
    Migliorino, Maria Rita
    Pluzanski, Adam
    Linke, Rolf Gerhard
    Sbar, Eric
    Wang, Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)
    Cheng, Ying
    Mok, Tony S.
    Zhou, Xiangdong
    Lu, Shun
    Zhou, Qing
    Zhou, Jianying
    Du, Yingying
    Yu, Ping
    Liu, Xiaoqing
    Hu, Chengping
    Lu, You
    Zhang, Yiping
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Linke, Rolf
    Wong, Chew Hooi
    Tang, Yiyun
    Zhu, Fanfan
    Wilner, Keith D.
    Wu, Yi-Long
    LUNG CANCER, 2021, 154 : 176 - 185
  • [25] Phase 2, Randomized, Open-Label Study of Ramucirumab in Combination With First-Line Pemetrexed and Platinum Chemotherapy in Patients With Nonsquamous, Advanced/Metastatic Non-Small Cell Lung Cancer
    Doebele, Robert C.
    Spigel, David
    Tehfe, Mustapha
    Thomas, Sachdev
    Reck, Martin
    Verma, Sunil
    Eakle, Janice
    Bustin, Frederique
    Goldschmidt, Jerome, Jr.
    Cao, Dachuang
    Alexandris, Ekaterine
    Yurasov, Sergey
    Camidge, D. Ross
    Bonomi, Philip
    CANCER, 2015, 121 (06) : 883 - 892
  • [26] Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
    O'Sullivan, Dylan E.
    Jarada, Tamer N.
    Yusuf, Amman
    Hu, Leo
    Gogna, Priyanka
    Brenner, Darren R.
    Abbie, Erica
    Rose, Jennifer B.
    Eaton, Kiefer
    Elia-Pacitti, Julia
    Ewara, Emmanuel M.
    Pabani, Aliyah
    Cheung, Winson Y.
    Boyne, Devon J.
    CURRENT ONCOLOGY, 2022, 29 (10) : 7198 - 7208
  • [27] Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
    Mok, Tony
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Rosell, Rafael
    Jaime, Jesus Corral
    Migliorino, Maria Rita
    Pluzanski, Adam
    Linke, Rolf Gerhard
    Sbar, Eric
    Wang, Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [28] Positive CHMP Recommendation for RYBREVANT® (Amivantamab) for Treatment of adult Patients with advanced non-small cell Lung Cancer and activating EGFR Exon20 Insertion Mutations after Failure of platinum-based Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (12)
  • [29] Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
    Planchard, David
    Smit, Egbert F.
    Groen, Harry J. M.
    Mazieres, Julien
    Besse, Benjamin
    Helland, Aslaug
    Giannone, Vanessa
    D'Amelio, Anthony M., Jr.
    Zhang, Pingkuan
    Mookerjee, Bijoyesh
    Johnson, Bruce E.
    LANCET ONCOLOGY, 2017, 18 (10): : 1307 - 1316
  • [30] Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Ken
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Lee, Ki Hyeong
    Lu, Shun
    Shi, Yuankai
    Kim, Sang-We
    Laskin, Janessa
    Kim, Dong-Wan
    Arvis, Catherine Dubos
    Kolbeck, Arvis Karl
    Laurie, Scott A.
    Tsai, Chun-Ming
    Shahidi, Mehdi
    Kim, Miyoung
    Massey, Dan
    Zazulina, Victoria
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2016, 17 (05): : 577 - 589
12345